Targeted Technology Fund - aVenture Asset Manager Research
Location
San Antonio, TX, US
Founded
2009
Targeted Technology Fund is an early-stage investment firm specializing in disruptive medical and life science innovations. The firm focuses on technologies that can significantly improve medical practices and patient outcomes, as well as those that enhance the efficiency, cost, or functionality of life science product development and manufacturing. Their typical investment rounds include Seed, Series A, Series B, and Series C stages.
Notable portfolio companies include Aerin Medical, Bi02 Medical, Bluegrass Vascular Technologies, Cardiovate, Dnatrix, StemBioSys, and Xenex. The firm prides itself on a hands-on investment philosophy, working closely with portfolio companies to accelerate their growth and success. Key partners and decision-makers bring extensive experience from leading roles in the medical and life sciences industries, ensuring valuable insights and strategic guidance for their investments.
Targeted Technology Fund - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages